KR102436692B1 - Composition comprising steamed mature silkworm products having silk protein for preventing or treating obesity - Google Patents
Composition comprising steamed mature silkworm products having silk protein for preventing or treating obesity Download PDFInfo
- Publication number
- KR102436692B1 KR102436692B1 KR1020200074840A KR20200074840A KR102436692B1 KR 102436692 B1 KR102436692 B1 KR 102436692B1 KR 1020200074840 A KR1020200074840 A KR 1020200074840A KR 20200074840 A KR20200074840 A KR 20200074840A KR 102436692 B1 KR102436692 B1 KR 102436692B1
- Authority
- KR
- South Korea
- Prior art keywords
- silkworm
- obesity
- silk protein
- cooked
- silkworms
- Prior art date
Links
- 241000255789 Bombyx mori Species 0.000 title claims abstract description 134
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 64
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 64
- 208000008589 Obesity Diseases 0.000 title claims abstract description 50
- 239000000203 mixture Substances 0.000 title claims abstract description 50
- 235000020824 obesity Nutrition 0.000 title claims abstract description 49
- 210000001596 intra-abdominal fat Anatomy 0.000 claims abstract description 36
- 239000004480 active ingredient Substances 0.000 claims abstract description 27
- 230000036541 health Effects 0.000 claims abstract description 27
- 235000013305 food Nutrition 0.000 claims abstract description 26
- 230000002265 prevention Effects 0.000 claims abstract description 17
- 230000009467 reduction Effects 0.000 claims abstract description 12
- 230000004584 weight gain Effects 0.000 claims abstract description 12
- 235000019786 weight gain Nutrition 0.000 claims abstract description 12
- 230000006872 improvement Effects 0.000 claims abstract description 8
- 238000012545 processing Methods 0.000 claims abstract description 8
- 239000000047 product Substances 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 238000010411 cooking Methods 0.000 claims description 16
- 235000013376 functional food Nutrition 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 230000009278 visceral effect Effects 0.000 claims description 14
- 230000008569 process Effects 0.000 claims description 12
- 230000037396 body weight Effects 0.000 claims description 10
- 208000011580 syndromic disease Diseases 0.000 claims description 8
- 206010020772 Hypertension Diseases 0.000 claims description 5
- 238000009825 accumulation Methods 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 235000015872 dietary supplement Nutrition 0.000 claims description 4
- 230000001629 suppression Effects 0.000 claims description 4
- 208000031104 Arterial Occlusive disease Diseases 0.000 claims description 3
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 3
- 208000021328 arterial occlusion Diseases 0.000 claims description 3
- 201000001421 hyperglycemia Diseases 0.000 claims description 3
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 3
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 3
- 235000013373 food additive Nutrition 0.000 claims description 2
- 239000002778 food additive Substances 0.000 claims description 2
- 238000007602 hot air drying Methods 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 20
- 239000003814 drug Substances 0.000 abstract description 13
- 230000002401 inhibitory effect Effects 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 230000001603 reducing effect Effects 0.000 abstract description 8
- 238000009366 sericulture Methods 0.000 abstract description 5
- 238000011161 development Methods 0.000 abstract description 4
- 235000018102 proteins Nutrition 0.000 description 51
- 239000000843 powder Substances 0.000 description 28
- 238000004519 manufacturing process Methods 0.000 description 13
- 239000003925 fat Substances 0.000 description 12
- 235000019197 fats Nutrition 0.000 description 11
- 238000009472 formulation Methods 0.000 description 10
- 239000013642 negative control Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 235000009200 high fat diet Nutrition 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000003579 anti-obesity Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 6
- 208000004611 Abdominal Obesity Diseases 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 229920000609 methyl cellulose Polymers 0.000 description 5
- 239000001923 methylcellulose Substances 0.000 description 5
- 235000010981 methylcellulose Nutrition 0.000 description 5
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical group CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 5
- 229960001243 orlistat Drugs 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 238000013116 obese mouse model Methods 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 235000014347 soups Nutrition 0.000 description 4
- 210000004003 subcutaneous fat Anatomy 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000002830 appetite depressant Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 210000002249 digestive system Anatomy 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- -1 etc. Substances 0.000 description 3
- 235000011194 food seasoning agent Nutrition 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 239000000883 anti-obesity agent Substances 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 238000009777 vacuum freeze-drying Methods 0.000 description 2
- 235000015192 vegetable juice Nutrition 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 238000004260 weight control Methods 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 241000190633 Cordyceps Species 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 241000958526 Cuon alpinus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 206010017999 Gastrointestinal pain Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 229940086609 Lipase inhibitor Drugs 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000382353 Pupa Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 235000021407 appetite control Nutrition 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000015190 carrot juice Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000019674 grape juice Nutrition 0.000 description 1
- 235000013882 gravy Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 230000001418 larval effect Effects 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000003880 negative regulation of appetite Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000000712 neurohormone Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 235000006286 nutrient intake Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940026547 orlistat 60 mg Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000015193 tomato juice Nutrition 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000003817 vacuum liquid chromatography Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/54—Proteins
- A23V2250/542—Animal Protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Insects & Arthropods (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Animal Husbandry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Child & Adolescent Psychology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
본 발명은 견사단백질을 갖는 익힌 누에가공물을 포함하는 비만의 예방 또는 치료용 조성물에 관한 것이다. 본 발명에 의해, 탁월한 내장 지방 감소 및 체중 증가 억제 효과를 발휘하는 견사단백질을 갖는 익힌 누에가공물을 유효성분으로 포함하는 비만의 예방, 치료 및 개선용 조성물이 제공됨에 따라, 본 발명을 이용한 각종 건강보조식품 또는 의약품이 개발되어 시판될 것으로 예상되는 바, 이로 인하여 견사선을 갖는 익힌 누에가공물의 활용도 창출 및 고부가가치화로 양잠 산업 발전에 기여하는 효과가 클 것으로 기대되며, 비만 및 이로 인해 야기되는 각종 성인병으로 인해 치솟는 사회적 비용의 감소 및 국민들의 삶의 질 개선에 크게 기여할 것으로 예상된다.The present invention relates to a composition for preventing or treating obesity, comprising a cooked silkworm product having silk protein. According to the present invention, there is provided a composition for prevention, treatment and improvement of obesity comprising a cooked silkworm processing product having silk protein, which exhibits excellent visceral fat reduction and weight gain inhibitory effect, as an active ingredient, and various health using the present invention It is expected that supplementary food or pharmaceuticals will be developed and marketed, which is expected to have a great effect on contributing to the development of the sericulture industry by creating the utilization of cooked silkworm processed products with silk thread and making it high value, obesity and various adult diseases caused by it This is expected to greatly contribute to reducing soaring social costs and improving the quality of life of the people.
Description
본 발명은 견사단백질을 갖는 익힌 누에가공물을 포함하는 비만의 예방 또는 치료용 조성물에 관한 것으로, 보다 자세하게는 5령4일부터 숙잠기까지의 누에로부터 선택되는 생누에를 물에 넣어 익히거나 또는 증기의 열로 익힌 견사단백질을 갖는 익힌 누에가공물을 포함하는 비만의 예방 또는 치료용 조성물에 관한 것이다. The present invention relates to a composition for the prevention or treatment of obesity comprising a cooked silkworm processed product having silk protein, and more particularly, to a raw silkworm selected from silkworms from 5th instar to 4th day of incubation in water to cook or steam. It relates to a composition for preventing or treating obesity, comprising a cooked silkworm processed product having silk protein cooked with heat.
비만은 지방의 과다 축적으로 특징 지워지는 다양한 원인을 가진 심각한 만성 증후군이다. 비만 치료의 목표는 크게 두 가지로서, 첫 번째는 과량의 지방을 연소시켜 체중을 감소시키는 것이며, 두 번째는 대사성 불균형을 개선시키는 것이다. 복부 비만을 보이는 환자는 흔히 X-증후군(인슐린 저항성, 제 2형 당뇨병, 고혈압 및 지질 대사 이상)과 같은 병적인 상태와 관련되어 있으며, 조기 동맥경화, 허혈성 심질환 및 뇌혈관 질환의 강력한 위험인자로 작용한다.Obesity is a serious chronic syndrome with a variety of causes characterized by excessive accumulation of fat. There are two main goals of obesity treatment, the first is to reduce weight by burning excess fat, and the second is to improve metabolic imbalance. Patients with abdominal obesity are often associated with pathological conditions such as X-syndrome (insulin resistance,
인체에서 에너지의 저장과 공급을 담당하는 지방은 피하지방과 내장지방으로 구분되는데, 엉덩이나 허벅지 등의 피부 아래에 분포하며 인체의 비상 상황에 대비하는 기능을 가진 피하지방과는 달리, 복부 내장 사이사이에 축적되는 내장지방은 복부에만 머물러 있지 않고 혈액 속에 지방산 형태로 돌아다니며 뇌혈관, 간, 심장 등에 쌓이게 된다. 이는 장기적으로 각종 대사증후군 및 심혈관계 질환 등을 유발하는 원인이 되는 동시에, 다양한 염증성 물질들을 분비시켜 이들이 혈액을 통해 이동하면서 체내 곳곳에 염증을 발생시킨다. 이렇듯, 영양분 섭취의 과잉과 운동 부족, 및 스트레스 등으로 체내에 과축적되는 내장지방은 현대인의 건강을 심각하게 위협하는 주요 원인 중 하나로 대두되고 있다.The fat that stores and supplies energy in the human body is divided into subcutaneous fat and visceral fat. The visceral fat that accumulates in between does not stay only in the abdomen, but travels in the form of fatty acids in the blood and accumulates in the blood vessels of the brain, liver, and heart. This causes various metabolic syndromes and cardiovascular diseases in the long term, and at the same time secretes various inflammatory substances, which move through the blood and cause inflammation throughout the body. As such, visceral fat, which is excessively accumulated in the body due to excessive nutrient intake, lack of exercise, and stress, is emerging as one of the major causes that seriously threaten the health of modern people.
즉, 순기능을 하는 피하지방과 달리 내장지방은 인슐린저항성을 촉발하여 2형당뇨와 고혈압, 지방간과 같은 대사질환의 근본 발생 원인이 될 뿐만 아니라, 이차적으로 심장병과 뇌졸중과 같은 혈관질환과 치매나 난청, 관절염과 같은 신경퇴행질환과 노화의 원인을 제공한다.In other words, unlike subcutaneous fat, which has a good function, visceral fat triggers insulin resistance and is the root cause of metabolic diseases such as
현재 사용되고 있는 비만 치료제들은 크게 식욕억제제, 지방흡수억제제, 에너지소비 촉진제로 분류된다. 이 중, 암페타민 유도제 등의 식욕억제제를 사용하는 약물 요법은 식욕억제 능력이 지속되지 못하고 일시적이며, 그에 따른 부작용인 두통, 불면증, 혈압상승, 긴장감, 불안, 환각증세, 현기증, 시력저하 등의 문제점을 유발한다. 대표적인 약물로는 시부트라민(Sibutramine)이 있다. 이는 뇌의 시상하부에 작용하여 식욕억제작용을 일으키는 것으로 알려져 있다. 식욕 조절에 작용하는 신경호르몬인 세로토닌(Serotonin)과 노르에피네프린(Norepinephrine)의 재흡수를 억제하여 식욕을 감소시켜 과식을 막고, 고에너지 섭취를 저해하여 체중을 감소시켜주는 약물이다. 이들 대부분의 식욕억제제의 경우, 혈압 상승의 부작용으로 인해 심장에 무리를 줄 수 있기 때문에 심혈관계 환자들에게는 이들 약물 사용을 금지하고 있다. 또한 지방흡수억제제는 올리스타트(Orlistat)가 있다. 올리스타트는 췌장 및 소화기계에서 분비되는 리파아제 억제제로 췌장 및 소화기계에서 분비되는 리파아제를 억제하여 지방의 흡수를 저해하고 체내 지방 축적을 억제시켜 체중감량 효과를 나타내는 약물이다. 그러나, 올리스타트는 지용성 비타민 흡수 저해하여 비타민 불균형을 초래할 수 있고, 장 경련과 가스에 의한 위 팽만감, 기름 섞인 대변 등을 유발하여 소화기계통에 불편함을 유발한다.Currently used anti-obesity drugs are broadly classified into appetite suppressants, fat absorption inhibitors, and energy consumption enhancers. Among these, drug therapy using appetite suppressants such as amphetamine inducers does not have the ability to suppress appetite and is temporary. causes A typical drug is sibutramine. It is known that it acts on the hypothalamus of the brain and causes appetite suppression. It is a drug that reduces appetite by inhibiting the reuptake of serotonin and norepinephrine, which are neurohormones that control appetite, and prevents overeating by inhibiting high energy intake, thereby reducing weight. In the case of most of these appetite suppressants, the use of these drugs is prohibited for patients with cardiovascular diseases because they can put a strain on the heart due to the side effect of increasing blood pressure. Another fat absorption inhibitor is Orlistat. Orlistat is a lipase inhibitor secreted from the pancreas and digestive system. It inhibits lipase secreted from the pancreas and digestive system to inhibit fat absorption and inhibit fat accumulation in the body, thereby reducing weight. However, orlistat inhibits the absorption of fat-soluble vitamins, which can lead to vitamin imbalance, and causes discomfort in the digestive system by causing intestinal cramps, gas-induced stomach bloating, and oily stools.
또한, 현재 시판하고 있는 비만치료제 및 다이어트 보조제는 체지방 감소제의 경우에는 지방과 단백질을 구분하지 않고 더욱이 지방보다 단백질이 더 쉽게 분해되며, 내장지방보다 피하지방을 더 많이 감소시키는 보조제들이 많다.In addition, obesity treatment and diet supplements currently on the market do not distinguish between fat and protein in the case of body fat reducing agents, and moreover, protein is more easily decomposed than fat, and there are many supplements that reduce subcutaneous fat more than visceral fat.
따라서, 인위적인 방법으로 사용되는 치료제가 아니라, 부작용이 없는 천연물에서 유래한 생약제 등을 보편적인 식품의 형태로 섭취하면서, 내장비만만을 선택하여 효과적으로 감소시킬 수 있는 새로운 비만 치료제의 개발이 필요한 실정이다. Therefore, there is a need to develop a new anti-obesity treatment that can effectively reduce visceral obesity by selecting only visceral obesity while consuming herbal medicines derived from natural products without side effects, etc. in the form of universal food, rather than an artificial treatment.
한편, 누에고치를 생산하는 양잠산업은 고조선시대부터 이어온 우리나라의 전통산업으로써 1970년대에는 연간 100만 상자 이상의 누에를 농가에서 사육하였으나, 경제발전과 고급 화학섬유의 영향으로 현재는 크게 위축된 상황이다. 이에, 현재의 양잠산업은 건조누에, 수번데기, 동충하초 등 건강기능식품원료를 생산하는 산업으로 전환하였는데, 그 중 농가의 주 생산품목은 5령3일 건조누에이다. 5령3일 건조누에를 이용하는 이유는 5령3일이 지나 5령 4일부터는 강도가 강한 견사단백질이 누에의 몸속에서 급속히 비대해져 식용으로 사용하기에 매우 어려워지기 때문이다. 견사단백질은 견사선의 형태로 누에 몸속에 저장되어 있다가 누에가 숙잠(grown-up silkworm; mature silkworm)이 되면 이 견사단백질을 뱉어내면서 실크의 원료인 누에고치를 짓게 된다. On the other hand, the sericulture industry that produces silkworm cocoons is a traditional industry in Korea that has been passed down since the Gojoseon era. In the 1970s, more than 1 million boxes of silkworms were bred in farmhouses a year, but due to economic development and the influence of high-quality chemical fibers, the silkworm industry is now greatly reduced. . Accordingly, the current sericulture industry has shifted to an industry that produces health functional food raw materials such as dried silkworm, pupa, and cordyceps, among them, the main production item of the farm is the 5-year-old 3-day dried silkworm. The reason for using dried silkworms for 3 days of 5 instar is that after 3 days of 5 instar and 4 days of 5 instar, the strong silk protein rapidly enlarges in the silkworm's body, making it very difficult to use as food. Silk protein is stored in the silkworm body in the form of silk glands, and when the silkworm becomes a mature silkworm (grown-up silkworm; mature silkworm), the silk protein is spit out and a cocoon, the raw material of silk, is built.
이처럼 식용가능한 시기를 지난 숙잠은 실크의 생산을 위한 용도로서 사용되는 것 이외에는 특별하게 이용되지 못하고 있었으나, 본 발명자들이 대한민국 등록특허 제10-1388455호와 대한민국 등록특허 제10-1546446호에서 처음으로 이러한 견사단백질이 함유된 누에를 가압 또는 상압 조건하에서 80~125℃로 익혀 이를 피부개선용 화장료 조성물로서 개발한 바 있다. As such, sukjam, which has passed the edible period, has not been particularly used except for being used for the production of silk. It has been developed as a cosmetic composition for skin improvement by cooking silkworms containing silk protein at 80 to 125°C under pressure or atmospheric pressure.
또한, 누에와 관련된 의약품에 관한 연구에 있어서는 주로 실크펩타이드와 관련된 연구만이 진행되고 있을 뿐, 이러한 견사단백질이 함유된 누에(또는 숙잠)를 활용한 연구는 미비한 편이고, 종래 숙잠을 활용하는 대부분의 방법은 누에에 함유된 모든 유용 활성물질을 함께 이용하는 것이 아닌 실크단백질만으로 이루어진 단순한 누에고치만을 이용하는 것으로서 섭취를 위한 누에고치의 가수분해 시 고가의 비용이 소요되고, 유용성분이 유실되는 문제점이 있었는바, 이를 해결하기 위해서는 실크단백질과 더불어 누에에 함유된 모든 성분을 함께 이용하는 것이 필요하다. In addition, in research on drugs related to silkworms, only studies related to silk peptides are mainly being conducted, and studies using silkworms (or sleep) containing such silk protein are incomplete, and most The method is not to use all the useful active substances contained in the silkworm together, but to use only a simple cocoon made of silk protein only. To solve this problem, it is necessary to use all the ingredients contained in silkworm along with silk protein.
따라서, 견사단백질을 갖는 익힌 누에는 생체적합하며 안전한 천연 물질이므로, 이를 적용하여 내장비만으로 인한 비만 및 관련 질환들을 치료할 수 있는 치료제로서 사용될 수 있을 것이다.Therefore, cooked silkworm with silk protein is a biocompatible and safe natural material, so it may be used as a therapeutic agent to treat obesity and related diseases caused by visceral obesity by applying it.
이러한 상황 하에서, 본 발명자들은 탁월하며 인체에 안전한 비만 치료제를 개발하기 위하여 예의 노력하였다. 그 결과, 본 발명자들은 견사단백질을 갖는 익힌 누에가공물(익힌 숙잠; 홍잠)이 비만 유발 모델에서 탁월하게 내장 지방을 감소시키고 체중 증가를 억제시키는 것을 최초로 발견하였고, 본 발명의 견사단백질을 갖는 익힌 누에가공물이 비만(특히, 내장지방형 비만)의 예방 및 치료 효과가 있음을 확인함으로써 본 발명을 완성하였다. Under these circumstances, the present inventors have made intensive efforts to develop an excellent and safe therapeutic agent for obesity. As a result, the present inventors have discovered for the first time that the processed cooked silkworm with silk protein (cooked sukjam; hongjam) excellently reduces visceral fat and suppresses weight gain in an obesity-inducing model, and cooked silkworm with silk protein of the present invention The present invention was completed by confirming that the processed product has a preventive and therapeutic effect on obesity (in particular, visceral fat-type obesity).
따라서, 본 발명의 일 목적은 견사단백질을 갖는 익힌 누에가공물을 유효성분으로 포함하는 비만의 예방 또는 치료용 약학적 조성물을 제공하는 데 있다.Accordingly, an object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of obesity comprising a cooked silkworm processing product having silk protein as an active ingredient.
또한, 본 발명의 다른 목적은 견사단백질을 갖는 익힌 누에가공물을 유효성분으로 포함하는 비만의 예방 또는 개선용 식품 조성물을 제공하는 데 있다.In addition, another object of the present invention is to provide a food composition for the prevention or improvement of obesity comprising a cooked silkworm processed product having silk protein as an active ingredient.
또한, 본 발명의 또 다른 목적은 견사단백질을 갖는 익힌 누에가공물을 유효성분으로 포함하는 체중 증가 억제 및 내장 지방 감소용 건강기능 식품 조성물을 제공하는 데 있다.In addition, another object of the present invention is to provide a health functional food composition for weight gain suppression and visceral fat reduction comprising a cooked silkworm processed product having silk protein as an active ingredient.
또한, 본 발명의 또 다른 목적은 견사단백질을 갖는 익힌 누에가공물을 유효성분으로 포함하는 비만으로 인한 합병증의 예방 또는 치료용 약학적 조성물을 제공하는 데 있다.In addition, another object of the present invention is to provide a pharmaceutical composition for preventing or treating complications due to obesity comprising a cooked silkworm processed product having silk protein as an active ingredient.
또한, 본 발명의 또 다른 목적은 견사단백질을 갖는 익힌 누에가공물을 유효성분으로 포함하는 비만으로 인한 합병증의 예방 또는 개선용 식품 조성물을 제공하는 데 있다.In addition, another object of the present invention is to provide a food composition for preventing or improving complications due to obesity comprising a cooked silkworm processed product having silk protein as an active ingredient.
본 명세서에서 사용한 용어는 단지 설명을 목적으로 사용된 것으로, 한정하려는 의도로 해석되어서는 안된다. 단수의 표현은 문맥상 명백하게 다르게 뜻하지 않는 한, 복수의 표현을 포함한다. 본 명세서에서, "포함하다" 또는 "가지다" 등의 용어는 명세서 상에 기재된 특징, 숫자, 단계, 동작, 구성요소, 부품 또는 이들을 조합한 것이 존재함을 지정하려는 것이지, 하나 또는 그 이상의 다른 특징들이나 숫자, 단계, 동작, 구성요소, 부품 또는 이들을 조합한 것들의 존재 또는 부가 가능성을 미리 배제하지 않는 것으로 이해되어야 한다.The terms used herein are used for the purpose of description only and should not be construed as limiting. The singular expression includes the plural expression unless the context clearly dictates otherwise. In the present specification, terms such as “comprise” or “have” are intended to designate that a feature, number, step, operation, component, part, or combination thereof described in the specification exists, but one or more other features It is to be understood that this does not preclude the possibility of the presence or addition of numbers, steps, operations, components, parts, or combinations thereof.
다르게 정의되지 않는 한, 기술적이거나 과학적인 용어를 포함해서 여기서 사용되는 모든 용어들은 실시예가 속하는 기술 분야에서 통상의 지식을 가진 자에 의해 일반적으로 이해되는 것과 동일한 의미를 가지고 있다. 일반적으로 사용되는 사전에 정의되어 있는 것과 같은 용어들은 관련 기술의 문맥 상 가지는 의미와 일치하는 의미를 가지는 것으로 해석되어야 하며, 본 출원에서 명백하게 정의하지 않는 한, 이상적이거나 과도하게 형식적인 의미로 해석되지 않는다.Unless defined otherwise, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by one of ordinary skill in the art to which the embodiment belongs. Terms such as those defined in a commonly used dictionary should be interpreted as having a meaning consistent with the meaning in the context of the related art, and should not be interpreted in an ideal or excessively formal meaning unless explicitly defined in the present application. does not
이하, 본 발명에 대하여 보다 상세히 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명의 일 양태에 따르면, 본 발명은 견사단백질을 갖는 익힌 누에가공물을 유효성분으로 포함하는 비만의 예방 또는 치료용 약학적 조성물을 제공한다.According to one aspect of the present invention, the present invention provides a pharmaceutical composition for preventing or treating obesity comprising a cooked silkworm processed product having silk protein as an active ingredient.
본 발명의 누에가공물은 생누에를 물에 넣어 익히거나 또는 증기의 열로 익혀 제조한 것으로써, 견사단백질이 모두 함유된 상태로 식이용으로 섭취가능한 것이 특징이다.The processed silkworm of the present invention is prepared by cooking raw silkworms in water or cooking them with steam heat, and is characterized in that it can be consumed for food while containing all silk protein.
본 명세서에서 유효성분을 언급하면서 사용되는 단어 "익힌 누에"는 명세서 내에서 익힌 숙잠 또는 홍잠과 혼용된다.The word "cooked silkworm" used while referring to the active ingredient in this specification is used interchangeably with cooked sukjam or hongjam in the specification.
종래 당업계에 누에 또는 실크펩타이드를 이용한 건강기능식품이 다양하게 이용되고 있으나, 실크펩타이드가 갖는 성분과 누에의 성분이 다름은 명백하며, 누에의 각 시기별에 있어서도 생것일 때와 이를 익혔을 때의 함유하고 있는 성분의 함량이 다름이 확인된다. In the prior art, health functional foods using silkworms or silk peptides are used in various ways in the art, but it is clear that the ingredients of silk peptides and those of silkworms are different. It is confirmed that the content of the components contained in the
따라서, 기존에는 식용하지 못하고 견사 생성용 누에고치를 만들기 위해 사육하는 것 이외에는 별다른 용도가 없었던 견사단백질을 갖는 누에를 견사단백질이 함유된 식이용으로 섭취할 수 있는 상태로 가공하여 비만의 예방 또는 치료용 조성물의 소재로 이용할 수 있다는 점에서 본 발명이 의의가 있다.Therefore, the prevention or treatment of obesity by processing silkworms with silk protein, which were not edible and had no particular use other than breeding to make cocoons for silk production, into a state that can be consumed for food containing silk protein. The present invention is meaningful in that it can be used as a material for a composition for use.
이에, 본 발명은 견사단백질을 갖는 익힌 누에가공물을 유효성분으로 함유하는 비만의 예방 또는 치료용 조성물 및 이를 포함하는 건강기능식품을 제공하기 위한 것으로써, 구체적인 실예로 상기 견사단백질을 갖는 익힌 누에가공물에 대해 다양한 효능, 즉, 상기 누에가공물이 내장지방 감소 및 체중 증가 억제 효과도 나타냄을 확인한 결과를 토대로 상기 견사단백질을 갖는 익힌 누에가공물은 비만, 특히 내장지방형인 비만을 예방하거나 또는 치료할 수 있는 비만의 예방 또는 치료용 조성물 또는 이를 포함하는 식품 조성물의 유효성분으로 적용가능하게 된다.Accordingly, the present invention is to provide a composition for the prevention or treatment of obesity containing the processed cooked silkworm product having silk protein as an active ingredient, and a health functional food comprising the same, as a specific example, the cooked silkworm processed product having the silk protein Based on the results of confirming that various effects, that is, the processed silkworm material also exhibits the effect of reducing visceral fat and inhibiting weight gain, the cooked silkworm product with the silk protein can prevent or treat obesity, especially obesity, which is a visceral fat type. It becomes applicable as an active ingredient of a composition for the prevention or treatment of or a food composition comprising the same.
본 명세서에서, 상기 견사단백질을 포함하고 있는 익힌 누에가공물은, 3면잠, 4면잠 등의 모든 누에를 익힌 과정을 통해 제조한 것을 의미하며, 바람직하게는 누에 중 5령4일의 4면잠 누에부터 숙잠기까지의 누에 중 어느 하나 이상을 선택하여 사용할 수 있으며, 더 바람직하게는 숙잠기의 누에를 사용하는 것이 가장 좋다. 이는, 5령3일의 누에도 사용할 수는 있으나 5령4일 이후의 누에에 비해서 누에가 갖는 견사단백질이 적은 편이기 때문에 본 발명이 목적하는 효능을 충분히 발휘하지 못할 우려가 있기 때문이다. In the present specification, the cooked silkworm processing product containing the silk protein means that it is prepared through the process of cooking all silkworms such as 3 silkworms and 4 silkworms, preferably from the 4 silkworms of 5 years of age and 4 days of silkworms. It is possible to select and use any one or more of the silkworms up to the deep submergence period, and more preferably, it is best to use the silkworms of the deep submergence period. This is because, although it can be used for silkworms of 5 years of age and 3 days of age, there is a fear that the present invention may not sufficiently exhibit the desired efficacy because the silk protein of the silkworms is small compared to silkworms after 5 years of age and 4 days.
한편, 숙잠기의 누에라 함은 누에 몸속에 견사단백질이 가득 차 있는 누에로서 고치를 짓기 전까지의 누에를 의미하는 것으로써, 숙잠기의 누에는 누에똥이 대부분 배출되어 있기 때문에 약학 조성물 또는 식품조성물(건강기능식품)의 유효성분으로 사용하기에 가장 적합하다. On the other hand, the silkworm of the deep sleep period is a silkworm that is full of silk protein in the silkworm body, and it means the silkworm before making a cocoon. It is most suitable for use as an active ingredient in health functional food).
본 발명에서는 상기와 같은 누에에 함유되어 있는 견사단백질까지 모두 식이 섭취 가능하도록 하기 위해 상기 누에를 가공하여 가공물 형태로 제조하여 약학 조성물 또는 식품조성물(건강기능식품)의 유효성분으로 사용한다.In the present invention, in order to make it possible to eat all the silk protein contained in the silkworm as described above, the silkworm is processed and manufactured in the form of a processed product, and it is used as an active ingredient of a pharmaceutical composition or a food composition (health functional food).
상기 유효성분인 익힌 누에가공물은 5령4일의 4면잠 누에부터 숙잠기까지의 누에 중에서 선택되는 생누에를 55 내지 125℃의 온도에서 30분 내지 24시간 동안 물에 넣어 익히거나 또는 증기의 열로 익혀 제조하며, 바람직하게는 상기 누에를 80 내지 125℃의 증기의 열로 100 내지 150분 동안 익혀 견사단백질이 모두 함유되도록 제조하는 것이 특징이다. 즉, 80℃ 미만의 증기 열로 150분을 초과하여 제조할 경우에는 제조시간이 너무 길어 오히려 견사단백질이 포함된 누에 자체가 갖고 있는 유효성분들이 파괴될 우려가 있으며, 125℃를 초과하여 100분 미만으로 제조할 경우에는 온도가 너무 높아 이 또한, 견사단백질이 포함된 누에 자체가 갖고 있는 유효성분들에 악영향을 미칠 우려가 있기 때문이다.The cooked silkworm process as the active ingredient is cooked by putting raw silkworms selected from silkworms from 5 instar and 4 days of sleep to deep sleep for 30 minutes to 24 hours at a temperature of 55 to 125° C., or by heat of steam. It is prepared by cooking, and preferably, the silkworm is cooked for 100 to 150 minutes with steam heat of 80 to 125° C. It is characterized in that it contains all the silk protein. That is, in the case of manufacturing over 150 minutes with steam heat of less than 80 ° C, the production time is too long, rather there is a risk that the active ingredients of the silkworm itself containing silk protein may be destroyed, and if it exceeds 125 ° C, less than 100 minutes This is because the temperature is too high in the case of manufacturing with this, and there is a risk of adversely affecting the active ingredients of the silkworm itself containing silk protein.
이러한, 상기 익힌 과정 후에는 통상의 방법으로 건조하여 분말형태로 제조하여 사용할 수 있으며, 바람직하게는 열풍건조 또는 진공동결건조 중 선택된 어느 하나를 통해 건조시켜 분말화하는 것이 좋으며, 유효성분의 손실을 최소화하기 위해서는 진공동결건조 방법이 가장 적합하다.After the above-mentioned cooking process, it can be dried and used in a powder form by a conventional method, preferably dried through either hot air drying or vacuum freeze drying to reduce the loss of active ingredients. In order to minimize it, the vacuum freeze-drying method is most suitable.
따라서, 본 발명의 익힌 누에가공물은 열풍건조 또는 진공동결건조물일 수 있다.Therefore, the cooked silkworm processed product of the present invention may be a hot air dried product or a vacuum freeze dried product.
상기 분말화는 가정용 믹서기, 해머밀, 롤러밀, 에어제트밀(동결분쇄) 등 어떠한 방법을 사용해도 무관하지만, 시료유실의 최소화, 성분 왜곡현상 방지 및 미세분말화를 위해서는 롤러밀에 의한 방법이 좋다. 보통 가정용 믹서기나 해머밀로 분쇄하면 분말입자의 크기가 0.1㎜정도 이하로 분쇄하기가 매우 어려운데 비하여, 롤러밀로 수차례 반복 분쇄하면 분말화된 입자의 크기가 평균 10㎛ 정도까지 미세분말화가 가능하여 섭취와 제품에 유리하게 작용할 것으로 예상된다.The powdering can be carried out by any method such as a household mixer, hammer mill, roller mill, air jet mill (freeze grinding), etc., but in order to minimize sample loss, prevent component distortion and fine powder, the method by a roller mill is preferred. good night. In general, when pulverizing with a household mixer or hammer mill, it is very difficult to pulverize the powder particles to a size of 0.1 mm or less. and products are expected to be beneficial.
또한, 상기 분말형태로 제조된 후에는 상기 익힌 누에가공물 분말을 추출물 형태로 제조할 수 있으며, 이때 물, 탄소수 1 내지 4개의 저급 알코올 또는 이들의 혼합용매로 추출하여 제조될 수도 있다. 상기 탄소수 1 내지 4개의 저급 알코올은 메탄올, 에탄올, 프로판올, 이소프로판올, 부탄올 및 이소부탄올로 이루어진 군에서 선택될 수 있다. 상기 물, 탄소수 1 내지 4개의 저급 알코올 또는 이들의 혼합용액은 익힌 숙잠 분말의 중량을 기준 1~40배 부피(1kg 기준 1~40ℓ를 사용할 수 있으며, 바람직하게는 5~40배 부피를 사용할 수 있다. 상기 추출물의 추출조건은 20~100℃에서 1~48시간일 수 있으며, 상기 과정은 1~4번까지 반복할 수 있다. In addition, after being prepared in the powder form, the cooked silkworm processed powder may be prepared in the form of an extract, and in this case, it may be prepared by extraction with water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof. The lower alcohol having 1 to 4 carbon atoms may be selected from the group consisting of methanol, ethanol, propanol, isopropanol, butanol and isobutanol. The water, lower alcohol having 1 to 4 carbon atoms, or a mixed solution thereof is 1 to 40 times the volume (1 to 40 liters based on 1 kg can be used, preferably 5 to 40 times the volume based on the weight of the cooked sukjam powder. The extraction conditions of the extract may be 1 to 48 hours at 20 to 100° C., and the process may be repeated 1 to 4 times.
또 다른 방법으로는, 상기 익힌 누에가공물 분말을 물, 탄소수 1 내지 4개의 저급 알코올 또는 이들의 혼합용매로 추출 농축하여 얻은 추출물에, 물을 가하여 현탁한 후, 바람직하게는 추출물의 중량의 1~1000배, 더 바람직하게는 1~500배, 가장 바람직하게는 1~50배의 물을 가하여 현탁한 후, 상기 현탁물에 헥산, 클로로포름, 에틸아세테이트, 및, 부탄올로 이루어진 군에서 선택되는 용매를 가하여 얻은 분획물로 제조할 수 있다. In another method, after adding water to the extract obtained by extracting and concentrating the cooked silkworm processed powder with water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof, water is added to suspend, preferably 1 to 1 of the weight of the extract After adding and suspending 1000 times, more preferably 1 to 500 times, and most preferably 1 to 50 times water, a solvent selected from the group consisting of hexane, chloroform, ethyl acetate, and butanol is added to the suspension. It can be prepared from the fraction obtained by adding
상기 추출물 또는 이의 분획물의 제조온도는 20 내지 100℃일 수 있으나, 이에 제한되는 것은 아니다. 추출 또는 분획 시간은 특별히 제한되는 것은 아니나, 10분 내지 2일 이내에 추출하는 것이 바람직하며, 추출용 기기로는 통상의 추출기기, 초음파분쇄추출기 또는 분획기를 이용할 수 있다. 이렇게 제조된 추출물 또는 분획물은 열풍건조, 감압건조 또는 동결건조하여 용매를 제거할 수 있다. 또한, 상기 추출물 또는 분획물은 칼럼크로마토그래피를 이용하여 정제하여 사용할 수도 있다. 상기 크로마토그래피는 실리카겔 컬럼 크로마토그래피(silica gel column chromatography), 엘에이취-20 컬럼 크로마토그래피(LH-20 column chromatography), 이온교환수지 크로마토그래피(ion exchange resin chromatography), 중압 액체 크로마토그래피(medium pressure liquid chromatography), 박층 크로마토그래피(TLC; thin layer chromatography), 실리카겔 진공 액체 크로마토그래피(silica gel vacuum liquid chromatography) 및 고성능 액체 크로마토그래피(high performance liquid chromatography) 중에서 선택될 수 있다. The manufacturing temperature of the extract or a fraction thereof may be 20 to 100 ℃, but is not limited thereto. The extraction or fractionation time is not particularly limited, but extraction is preferably within 10 minutes to 2 days, and a conventional extraction device, an ultrasonic crushing extractor or a fractionator may be used as the extraction device. The thus-prepared extract or fraction may be dried with hot air, dried under reduced pressure, or freeze-dried to remove the solvent. In addition, the extract or fraction may be purified and used using column chromatography. The chromatography is silica gel column chromatography (silica gel column chromatography), LH-20 column chromatography (LH-20 column chromatography), ion exchange resin chromatography (ion exchange resin chromatography), medium pressure liquid chromatography (medium pressure liquid chromatography) chromatography), thin layer chromatography (TLC), silica gel vacuum liquid chromatography, and high performance liquid chromatography may be selected.
본 발명에서, 상기 익힌 누에가공물의 누에 품종은 백견품종, 황견품종, 녹견품종 및 홍견품종으로 이루어진 군으로부터 선택된 1 종 이상일 수 있으며, 본 발명이 목적하는 항비만 효과로서 내장지방을 획기적으로 감소시키는 동시에 체중의 증가도 탁월하게 억제되는 효과가 발휘되는 한, 상기 익힌 누에가공물의 누에 품종으로는 어떠한 품종의 누에를 사용하여도 무관하다.In the present invention, the silkworm variety of the cooked silkworm processed product may be at least one selected from the group consisting of white dog breed, yellow dog breed, green dog breed, and red dog breed, and the present invention aims to reduce visceral fat dramatically as an anti-obesity effect. At the same time, it does not matter which type of silkworm is used as the silkworm variety of the cooked silkworm processed product as long as the effect of suppressing the increase in weight is excellently exhibited.
항비만은 지방세포 분화 및 지방생성 억제, 체지방 또는 체중의 감소, 지방세포 크기 감소, 복부 내장 지방 조직 억제, 복부 내장 조직 내 지방 축적 억제 효과를 의미하며, 이로 인해 체중 감량 및 비만, 특히 내장 지방형 비만의 개선 효과를 가질 수 있다. Anti-obesity refers to the effect of inhibiting adipocyte differentiation and adipogenesis, reducing body fat or body weight, reducing the size of adipocytes, inhibiting abdominal visceral adipose tissue, and inhibiting fat accumulation in abdominal visceral tissue, resulting in weight loss and obesity, especially visceral adipose It may have an effect of improving obesity.
이러한 상기 본 발명의 약학 조성물에는 상기 익힌 누에가공물이 본 발명의 약학 조성물에 0.001~100 중량%로 하여 첨가될 수 있다. 상기 약학 조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 상기 약학 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 사카린, 나한과 추출물(몬그로사이드), 스테비아, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 본 발명의 조성물에 적어도 하나 이상의 부형제, 예를 들면, 전분, 탄산칼슘, 수크로스 또는 락토오스, 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜, 폴리에틸렌글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다. In the pharmaceutical composition of the present invention, the cooked silkworm process may be added in an amount of 0.001 to 100% by weight to the pharmaceutical composition of the present invention. The pharmaceutical composition may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc., oral dosage forms, external preparations, suppositories, and sterile injection solutions according to conventional methods, respectively. Carriers, excipients and diluents that may be included in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, saccharin, Nahan fruit extract (mongroside), stevia, starch, acacia Gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. can In the case of formulation, it is prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants that are usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and such solid preparations include at least one excipient in the composition of the present invention, for example, starch, calcium carbonate, sucrose or lactose; It is prepared by mixing gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral use include suspensions, solutions, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients, for example, wetting agents, sweeteners, fragrances, preservatives, etc. may be included. . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Non-aqueous solvents and suspending agents include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. As a base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin, and the like can be used.
본 발명의 약학 조성물의 투여량은 치료받을 대상의 연령, 성별, 체중과, 치료할 특정 질환 또는 병리 상태, 질환 또는 병리 상태의 심각도, 투여경로 및 처방자의 판단에 따라 달라질 것이다. 이러한 인자에 기초한 투여량 결정은 당업자의 수준 내에 있으며, 일반적으로 투여량은 0.01㎎/㎏/일 내지 대략 2000㎎/㎏/일의 범위이다. 더 바람직한 투여량은 1㎎/㎏/일 내지 500㎎/㎏/일이다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다. The dosage of the pharmaceutical composition of the present invention will vary depending on the age, sex, and weight of the subject to be treated, the specific disease or pathological condition to be treated, the severity of the disease or pathological condition, the route of administration, and the judgment of the prescriber. Dosage determination based on these factors is within the level of one of ordinary skill in the art, and dosages generally range from 0.01 mg/kg/day to approximately 2000 mg/kg/day. A more preferred dosage is 1 mg/kg/day to 500 mg/kg/day. Administration may be administered once a day, or may be administered in several divided doses. The above dosage does not limit the scope of the present invention in any way.
본 발명의 약학 조성물을 투여 받는 대상은 쥐, 가축, 인간 등의 모든 포유동물을 포함하나, 투여 대상에게서 목적하는 효과가 발휘되는 한, 이에 한정되지 않는다.The subject to be administered the pharmaceutical composition of the present invention includes all mammals such as rats, livestock, and humans, but is not limited thereto as long as the desired effect is exhibited in the subject to be administered.
또한, 본 발명의 약학 조성물은 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁내 경막 또는 뇌혈관내 주사에 의해 투여될 수 있다. 본 발명의 조성물은 독성 및 부작용이 거의 없으므로 예방 목적으로 장기간 복용시에도 안심하고 사용할 수 있는 약제이다. In addition, the pharmaceutical composition of the present invention may be administered by various routes. All modes of administration can be envisaged, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebrovascular injection. Since the composition of the present invention has almost no toxicity and side effects, it is a drug that can be safely used even when taken for a long period of time for prophylactic purposes.
이때, 상기 익힌 누에가공물은 본 발명이 목적하는 효능을 나타내기 위한 유효한 함량으로, 분말 중량면에서 조성물 총 중량에 대하여 0.01~100 중량%로 함유하는 것이 바람직하고, 더욱 바람직하게는 0.1~90 중량%로 함유하는 것이 좋다. At this time, the cooked silkworm processed product is an effective content for exhibiting the desired efficacy of the present invention, and it is preferably contained in an amount of 0.01 to 100% by weight based on the total weight of the composition in terms of powder weight, and more preferably 0.1 to 90% by weight. It is better to contain it in %.
또한, 본 발명의 다른 양태에 따르면, 본 발명은 상기 익힌 누에가공물을 유효성분으로 포함하는 비만 예방 및 개선 효과를 위한 식품 조성물을 제공한다.In addition, according to another aspect of the present invention, the present invention provides a food composition for preventing and improving obesity comprising the cooked silkworm processed product as an active ingredient.
상기 식품 조성물은 건강기능식품, 식품 첨가제 또는 식이보조제이다.The food composition is a health functional food, food additive or dietary supplement.
또한, 본 발명은 견사단백질을 갖는 익힌 누에가공물을 유효성분으로 포함하는 체중 증가 억제 및 내장 지방 감소용 건강기능 식품 조성물을 제공한다. In addition, the present invention provides a health functional food composition for weight gain suppression and visceral fat reduction comprising a cooked silkworm processed product having silk protein as an active ingredient.
본 발명의 견사단백질을 갖는 익힌 누에 가공물은 체중 감소 효과, 내장 지방 감소 효과가 있으므로 체중 조절용 건강기능식품, 내장 지방 감소용 건강기능식품, 예컨대, 체중 감량 효과 및 내장 지방 감소가 개선된 다이어트용 건강식품 조성물으로 유용하게 사용될 수 있다.The cooked silkworm processed product with silk protein of the present invention has a weight reduction effect and visceral fat reduction effect, so a health functional food for weight control, a health functional food for visceral fat reduction, such as a diet health with improved weight loss effect and visceral fat reduction It can be usefully used as a food composition.
이때, 상기 익힌 누에가공물은 본 발명의 식품 조성물에 0.01~100 중량%로 하여 사용될 수 있다. 본 발명의 식품 조성물은 정제, 캡슐제, 환제 또는 액제 등의 형태를 포함하는 것으로서, 각종 드링크제, 육류, 소세지, 빵, 캔디류, 스넥류, 면류, 아이스크림, 유제품, 스프, 이온음료, 음료수, 알코올 음료, 껌, 차 및 비타민 복합제 등이 있다.In this case, the cooked silkworm processed product may be used in an amount of 0.01 to 100% by weight in the food composition of the present invention. The food composition of the present invention is in the form of tablets, capsules, pills or liquids, and various drinks, meat, sausages, breads, candies, snacks, noodles, ice cream, dairy products, soups, ionic drinks, beverages, alcoholic beverages. , gum, tea, and vitamin complexes.
또한, 본 발명의 또 다른 양태에 따르면, 본 발명은 상기 익힌 누에가공물을 유효성분으로 포함하는 비만으로 인한 합병증의 예방 또는 치료용 약학적 조성물; 또는 개선용 식품 조성물을 제공한다.In addition, according to another aspect of the present invention, the present invention provides a pharmaceutical composition for preventing or treating complications due to obesity comprising the cooked silkworm processed product as an active ingredient; Or it provides a food composition for improvement.
상기 비만으로 인한 합병증은 내장 지방 증후군, 대사이상 증후군, 고트리글리세라이드 혈증, 저HDL 혈증, 협심증, 심근경색, 골관절염, 기립성 저혈압, 폐고혈압, 제2형 당뇨병, 고혈압, 손상된 내당력, 관상동맥혈전증, 아테롬성동맥경화증, 담석증, 인슐린 저항성, 만성 동맥폐색증, 혈전색전증, 심장질환, 지질증후군 및 과혈당증으로 구성된 군으로부터 선택되는 1 종 이상일 수 있다.Complications due to obesity include visceral fatty syndrome, metabolic syndrome, hypertriglyceridemia, hypoHDLemia, angina pectoris, myocardial infarction, osteoarthritis, orthostatic hypotension, pulmonary hypertension,
비만은 그 증상들로 하여금 독립적인 질환으로 볼 수 있으나, 그보다 다른 질환을 유발시키는 원인이 되기 때문에 합병증과 같은 병적인 상태와 관련되어 있다. 따라서, 이러한 비만에 본 발명의 익힌 누에가공물이 효과적이므로, 비만에 의해 유발되는 합병증에도 효과적으로 작용한다.Obesity can be viewed as an independent disease, but it is related to pathological conditions such as complications because it causes other diseases. Therefore, since the cooked silkworm processed product of the present invention is effective for such obesity, it also effectively acts on complications caused by obesity.
본 발명의 조성물은 상술한 누에가공물을 유효성분으로 포함하므로, 중복된 내용은 본 명세서의 과도한 복잡성을 피하기 위하여 그 기재를 생략한다.Since the composition of the present invention includes the above-mentioned silkworm processing product as an active ingredient, the duplicated content is omitted to avoid excessive complexity of the present specification.
종합적으로, 본 발명은, 새로운 형태의 식의약용 원료인 익힌숙잠을 섭취할 경우 내장지방을 피하지방 대비 획기적으로 감소시키는 동시에 체중의 증가도 탁월하게 억제시킬 수 있다는 것을 최초로 규명한 것으로서, 본 발명을 이용한 각종 내장지방 감소 및 비만 억제 건강 보조제 또는 의약품이 개발되어 시판될 것으로 예상되며, 이로 인하여 내장지방 및 비만에 기인한 각종 성인병 및 스트레스 등으로 고통받는 수많은 국민들에게 익힌숙잠의 가치가 크게 부각될 것으로 기대된다. 또한, 익힌숙잠의 활용도 창출 및 고부가가치화로 양잠산업 및 농업 발전에 기여하는 효과 역시 클 것으로 기대된다.Overall, the present invention is the first to prove that visceral fat can be remarkably reduced compared to subcutaneous fat and, at the same time, weight gain can be excellently suppressed when ingesting a new type of raw material for food and medicine, cooked sleep. Various visceral fat reduction and obesity suppression health supplements or medicines are expected to be developed and marketed using is expected to be In addition, it is expected that the effect of contributing to the development of the sericulture industry and agriculture is expected to be great by creating the utilization of cooked sleep and increasing the added value.
본 발명에 의해, 탁월한 내장 지방 감소 및 체중 증가 억제 효과를 발휘하는 견사단백질을 갖는 익힌 누에가공물(익힌숙잠 동결건조 분말)을 유효성분으로 포함하는 비만(바람직하게는, 내장지방형 비만)의 예방, 치료 및 개선용 조성물이 제공된다. 본 발명을 이용한 각종 건강보조식품 또는 의약품이 개발되어 시판될 것으로 예상되는 바, 이로 인하여 견사선을 갖는 익힌 누에가공물의 활용도 창출 및 고부가가치화로 양잠 산업 발전에 기여하는 효과가 클 것으로 기대되며, 비만 및 이로 인해 야기되는 각종 성인병으로 인해 치솟는 사회적 비용(보건의료 비용 등)의 감소 및 국민들의 삶의 질 개선에 크게 기여할 것으로 예상된다.According to the present invention, the prevention of obesity (preferably, visceral fat-type obesity) comprising, as an active ingredient, a cooked silkworm processed product (cooked sukjam freeze-dried powder) with silk protein, which exhibits excellent effects of reducing visceral fat and inhibiting weight gain, Compositions for treatment and improvement are provided. It is expected that various health supplements or pharmaceuticals using the present invention will be developed and marketed, thereby contributing to the development of the sericulture industry by creating the utilization of the cooked silkworm process with silk thread and making it high value. It is expected to greatly contribute to the reduction of the soaring social costs (health and medical expenses, etc.) caused by various adult diseases and to improve the quality of life of the people.
도 1은 다양한 대조군 마우스 및 본 발명의 견사단백질을 갖는 익힌 숙잠 동결건조 분말(SMSP)을 경구투여한 마우스의 체중 증가 억제 수준을 비교한 결과를 보여준다(*p<0.05 및 #p<0.01, 음성 대조군 대비).
도 2는 음성 대조군 마우스(A) 및 본 발명의 견사단백질을 갖는 익힌 숙잠 동결건조 분말(SMSP)을 경구투여한 마우스(B)의 내장지방 수준을 비교한 이미지를 보여준다.
도 3은 다양한 대조군 마우스 및 본 발명의 견사단백질을 갖는 익힌 숙잠 동결건조 분말(SMSP)을 경구투여한 마우스의 내장지방 무게 수준을 비교한 결과를 보여준다(#p<0.01, 음성 대조군 대비).
도 4는 음성 대조군 마우스(A) 및 본 발명의 견사단백질을 갖는 익힌 숙잠 동결건조 분말(SMSP)을 경구투여한 마우스(B)의 적출 내장지방 양을 비교한 이미지를 보여준다. 1 shows the results of comparison of the weight gain inhibition level of various control mice and mice orally administered with a cooked sleep lyophilized powder (SMSP) having silk protein of the present invention (* p <0.05 and # p <0.01, negative) compared to control).
Figure 2 shows an image comparing the visceral fat level of a negative control mouse (A) and a mouse (B) orally administered with a cooked sleep lyophilized powder (SMSP) having silk protein of the present invention.
Figure 3 shows the results of comparison of the visceral fat weight level of various control mice and mice orally administered with cooked sukjam freeze-dried powder (SMSP) having silk protein of the present invention (# p <0.01, compared to negative control).
Figure 4 shows an image comparing the amount of extracted visceral fat of a negative control mouse (A) and a mouse (B) orally administered with a cooked sukjam freeze-dried powder (SMSP) having silk protein of the present invention.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 예시하기 위한 것으로서, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지는 않는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail through examples. These examples are only for illustrating the present invention, and it will be apparent to those of ordinary skill in the art that the scope of the present invention is not to be construed as being limited by these examples.
실시예 1. 견사단백질을 갖는 익힌 숙잠 동결건조 분말(steamed mature silkworm powder; SMSP)의 제조Example 1. Preparation of steamed mature silkworm powder (SMSP) having silk protein
1. 익힌 누에가공물(익힌 숙잠; 홍잠) 제조1. Manufacture of processed silkworms (cooked sukjam; hongjam)
누에를 사육하여 5령4일 이후 숙잠이 되면 100℃ 수증기로 2시간 동안 익혀 익힌 누에 가공물을 제조하였다.After breeding the silkworms and after 4 days of age of 5, when they fall asleep, cooked silkworm products were prepared by cooking them with steam at 100° C. for 2 hours.
2. 분말형태로 제조2. Manufactured in powder form
상기 익힌 누에가공물은 24 시간 동안 진공동결건조한 후, 롤러밀을 이용하여 0.1mm이하의 직경을 가지는 분말형태로 제조하고, 상기 익힌숙잠 동결건조 분말(steamed mature silkworm powder; SMSP)을 하기 실시예에 이용하였다. The cooked silkworm processed product was vacuum freeze-dried for 24 hours, prepared in a powder form having a diameter of 0.1 mm or less using a roller mill, and the steamed mature silkworm powder (SMSP) was used in the following examples. was used.
한편, 성분 분석 결과, 익히기 전의 숙잠 내에 있던 각종 구성성분의 함량이 익힌 숙잠이 되면서 다양하게 변화된 것을 확인하였다. On the other hand, as a result of the component analysis, it was confirmed that the contents of various components in the deep sleep before cooking changed in various ways as it became the cooked sleep.
특히, 조단백질의 함량에서 세린, 글리신, 알라닌의 함량이 현저하게 증가한 것을 알 수 있으며 이러한 익힌 숙잠의 성분 변화로 인해 상기 익힌 숙잠이 갖는 약리학적 효과에도 변화가 있을 것임을 확인할 수 있다. In particular, it can be seen that the contents of serine, glycine, and alanine are significantly increased in the content of the crude protein, and it can be confirmed that there will be a change in the pharmacological effect of the cooked sukjam due to the change in the components of the cooked sukjam.
실험예 1. 익힌 누에가공물 적용에 따른 체중 및 내장 지방 무게 변화 확인Experimental Example 1. Confirmation of changes in body weight and visceral fat weight according to the application of cooked silkworm processing
본 발명자들은 상기 실시예 1에서 제조된 본원발명의 SMSP(Steamed Mature Silkworm Powder)의 항 비만 효과를 확인하였다.The present inventors confirmed the anti-obesity effect of SMSP (Steamed Mature Silkworm Powder) of the present invention prepared in Example 1 above.
간략하게는, 다음과 같다:Briefly, it is as follows:
당업계에서 내장지방 측정 및 체중 관련 연구에 광범위하게 활용되어 온 고지방식이-비만 유발 ICR 마우스를 대상으로 하여 in vivo 동물 실험을 통해 SMSP의 활성을 검정하였다. A high-fat diet-obesity-induced ICR mouse, which has been extensively used for visceral fat measurement and weight-related studies in the art, was tested for SMSP activity through an in vivo animal experiment.
이를 위해, 5 주령의 수컷 ICR 마우스를 구입하여 온도 22±2℃, 상대 습도 55±5%, 12시간 명암 주기의 조건을 갖춘 동물 사육실에서 5주 동안 환경 적응 후, 하기와 같이 군 분리를 실시하였다:To this end, a 5-week-old male ICR mouse was purchased, acclimatized to the environment for 5 weeks in an animal breeding room equipped with the conditions of temperature 22±2℃, relative humidity 55±5%, and a 12-hour light-dark cycle, and then grouped as follows. said:
(i) 음성 대조군; 고지방식이-비만 마우스에게 담체인 0.5% 메틸 셀룰로오스(methyl cellulose) 10 ml/kg을 1일 1회씩 8주 동안 경구투여,(i) negative control; Oral administration of 10 ml/kg of 0.5% methyl cellulose as a carrier to obese mice on a high-fat diet once a day for 8 weeks,
(ii) 비교 대조군으로서 당업계에 공지된 비만치료제인 올리스타트(orlistat)를 투여한 올리스타트(orlistat) 투여군; 고지방식이-비만 마우스에게 0.5% 메틸 셀룰로오스(methyl cellulose)에 현탁시킨 올리스타트 60 mg/10 ml/kg을 1일 1회씩 8주 동안 경구투여; (ii) an orlistat-administered group administered with orlistat, an anti-obesity agent known in the art as a comparative control; Oral administration of orlistat 60 mg/10 ml/kg suspended in 0.5% methyl cellulose to obese mice on a high-fat diet once a day for 8 weeks;
(iii) 비교 대조군으로서 5령 3일 누에 동결건조 분말인 FDSP(freeze-dried, 3rd day of 5th instar silkworm larval powder)를 투여한 FDSP 투여군; 고지방식이-비만 마우스에게 0.5% 메틸 셀룰로오스(methyl cellulose)에 현탁시킨 FDSP 1 g/10 ml/kg을 1일 1회씩 8주 동안 경구투여, 및(iii) FDSP administration group administered with FDSP (freeze-dried, 3rd day of 5th instar silkworm larval powder), which is a freeze-dried powder of 5th 3rd day silkworm as a comparative control; Oral administration of 1 g/10 ml/kg of FDSP suspended in 0.5% methyl cellulose to obese mice on a high-fat diet once a day for 8 weeks, and
(iv) 실험군으로서 본원발명의 SMSP를 투여한 SMSP 투여군; 고지방식이-비만 마우스에게 0.5% 메틸 셀룰로오스에 현탁시킨 SMSP 1 g/10 ml/kg을 매일 1회씩 8주 동안 경구투여.(iv) SMSP administration group administered SMSP of the present invention as an experimental group; 1 g/10 ml/kg of SMSP suspended in 0.5% methyl cellulose was orally administered to obese mice on a high-fat diet once daily for 8 weeks.
상기 마우스들의 체중을 주 1회 측정하여 대조군들과 SMSP 투여군의 체중 변화 양상을 비교 분석하였고, 실험 최종일에는, 마우스를 안락사시킨 후 개복하여 내부 장기의 이상 유무를 확인한 후, 복부 장기에 생성된 내장지방을 모두 채취하여 그 무게를 측정하였다.The weight of the mice was measured once a week and the changes in body weight of the control group and the SMSP-administered group were compared and analyzed. All fats were collected and their weight was measured.
그 결과, 도 1에 나타낸 바와 같이, 실험 개시 1주 후부터 종료 시점까지 전 구간에서 대조군들과 SMSP 투여군의 체중은 유의한 차이를 나타냈다.As a result, as shown in FIG. 1 , the body weights of the control group and the SMSP-administered group showed a significant difference in all sections from one week after the start of the experiment to the end time.
구체적으로, 8 주 후 평균 체중이, 음성 대조군은 5.8±1.0 g 증가(37.5±0.4 g → 43.4±1.2 g; 15.5% 증가); 및 FDSP 투여군은 5.6±1.2 g 증가(37.5±0.3 g → 43.1±1.4 g; 15.1% 증가)한 반면, 본원발명의 SMSP 투여군은 단지 0.5±1.4 g 증가(37.7±0.4 g → 38.2±1.2 g; 1.2% 증가)하여 거의 증가하지 않은 것으로 나타났다. Specifically, the average body weight after 8 weeks, the negative control group increased by 5.8±1.0 g (37.5±0.4 g → 43.4±1.2 g; 15.5% increase); And the FDSP administration group increased by 5.6±1.2 g (37.5±0.3 g → 43.1±1.4 g; 15.1% increase), whereas the SMSP administration group of the present invention only increased by 0.5±1.4 g (37.7±0.4 g → 38.2±1.2 g; 1.2% increase), which showed almost no increase.
특히, SMSP 투여군 5 마리 중 3마리는 최종일의 체중이 실험 개시일의 체중보다 오히려 소폭 감소하였다.In particular, 3 out of 5 animals in the SMSP-administered group showed a slight decrease in body weight on the last day rather than the body weight at the start of the experiment.
즉, 실험을 실시한 8 주 동안 고지방식이를 급여하여 체중이 늘어난 다른 대조군들과 달리, 본원발명의 SMSP 투여군은 마찬가지로 고지방식이를 급여했음에도 불구하고, 실험 개시때와 거의 동일한 수준의 체중을 유지했다는 것은 본원발명의 SMSP가 체중 조절에 효과적임을 보여준다.That is, unlike the other control groups, who gained weight by feeding a high-fat diet for 8 weeks during the experiment, the SMSP-administered group of the present invention maintained almost the same body weight as at the start of the experiment, even though the high-fat diet was also fed. It shows that the SMSP of the present invention is effective for weight control.
또한, 도 2에 나타낸 바와 같이, 육안소견 상으로도, 음성 대조군에 비해 본원발명의 SMSP 투여군의 내장 지방량이 현저하게 감소된 것을 알 수 있다.In addition, as shown in FIG. 2 , it can be seen that the amount of visceral fat in the SMSP-administered group of the present invention was significantly reduced compared to the negative control group, even on the gross observations.
또한, 도 3에 나타낸 바와 같이, 실험 종료 후 측정한 대조군들과 SMSP 투여군의 내장지방 무게는 유의한 차이를 나타냈다.In addition, as shown in FIG. 3 , the visceral fat weight of the control group and the SMSP-administered group measured after the end of the experiment showed a significant difference.
구체적으로, 8주 후 평균 내장지방 무게는, 음성 대조군은 1,951±98 mg; 올리스타트 투여군은 1280±302 mg; 및 FDSP 투여군은 1684±270 mg로 나타난 반면, 본원발명의 SMSP 투여군은 단지 630±58 mg으로 나타났고, 특히, 음성 대조군과 비교했을 때는 무려 3 배 이상의 차이를 보였다.Specifically, the average visceral fat weight after 8 weeks was 1,951±98 mg for the negative control group; Orlistat administration group was 1280±302 mg; and FDSP administration group appeared as 1684±270 mg, whereas the SMSP administration group of the present invention showed only 630±58 mg, and in particular, compared with the negative control group, it showed a whopping 3 times or more difference.
즉, 다른 대조군들의 내장지방 무게 수준에 비해, 본원발명의 SMSP 투여군을 처리한 경우 현저히 적은 무게가 나온 것은 본원발명의 SMSP가 내장비만 감소 및 내장 지방 축적 억제에 효과적임을 보여준다.That is, compared to the visceral fat weight level of other controls, the fact that the SMSP-administered group of the present invention produced significantly less weight shows that the SMSP of the present invention is effective in reducing visceral obesity and inhibiting visceral fat accumulation.
또한, 도 4에 나타낸 바와 같이, 육안소견 상으로도, 음성 대조군에 비해 본원발명의 SMSP 투여군의 내장 지방량이 현저하게 감소된 것을 알 수 있다.In addition, as shown in FIG. 4 , it can be seen that the amount of visceral fat of the SMSP-administered group of the present invention was significantly reduced compared to the negative control group, even on the macroscopic view.
따라서, 본 발명의 SMSP 경구투여 시 탁월한 체중 증가 억제 효과 및 내장지방 감소 효과를 나타냄을 확인할 수 있었다. 이는 본 발명의 새로운 형태의 식의약용 원료인 익힌숙잠의 동결건조 분말을 섭취할 경우, 각종 성인병의 원인이 되는 내장지방이 획기적으로 감소하는 동시에 체중 증가도 크게 억제된다는 것을 규명한 것이다.Therefore, it was confirmed that the SMSP of the present invention exhibited an excellent weight gain inhibitory effect and a visceral fat reduction effect upon oral administration. This proves that when the freeze-dried powder of fermented sleep, which is a raw material for food and medicine in a new form of the present invention, is consumed, visceral fat, which is the cause of various adult diseases, is dramatically reduced, and weight gain is also greatly suppressed.
이상 상기 실험결과를 토대로, 견사단백질을 갖는 익힌 누에가공물을 유효성분으로 포함하는 비만의 예방 및 치료용 조성물이 제공됨에 따라, 각종 항비만 건강기능식품 또는 의약품의 천연물 소재제공이 가능해짐으로 인해 국민건강증진과 보건의료 비용감소 등에 큰 기여를 할 것으로 기대된다.Based on the above experimental results, as a composition for prevention and treatment of obesity including a cooked silkworm processed material with silk protein as an active ingredient is provided, it is possible to provide natural materials for various anti-obesity health functional foods or medicines. It is expected to contribute greatly to health promotion and reduction of health care costs.
상기의 본 발명은 바람직한 실시예를 중심으로 살펴보았으며, 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자는 본 발명의 본질적 기술 범위 내에서 상기 본 발명의 상세한 설명과 다른 형태의 실시예들을 구현할 수 있을 것이다. 여기서 본 발명의 본질적 기술범위는 특허청구범위에 나타나 있으며, 그와 동등한 범위 내에 있는 모든 차이점은 본 발명에 포함된 것으로 해석되어야 할 것이다.The present invention has been looked at with a focus on preferred embodiments, and those of ordinary skill in the art to which the present invention pertains can implement embodiments other than the detailed description of the present invention within the essential technical scope of the present invention. will be able Here, the essential technical scope of the present invention is indicated in the claims, and all differences within the scope equivalent thereto should be construed as being included in the present invention.
<제제예 1. 약학적 제제><Formulation Example 1. Pharmaceutical formulation>
실시예 1의 견사단백질을 갖는 익힌 누에가공물 분말 200g을 락토오스 175.9g, 감자전분 180g 및 콜로이드성 규산 32g과 혼합하였다. 이 혼합물에 10% 젤라틴 용액을 첨가시킨 후, 분쇄해서 14 메쉬체를 통과시켰다. 이것을 건조시키고 여기에 감자전분 160g, 활석 50g 및 스테아린산 마그네슘 5g을 첨가해서 얻은 혼합물을 정제로 만들었다. 200 g of the cooked silkworm powder having the silk protein of Example 1 was mixed with 175.9 g of lactose, 180 g of potato starch and 32 g of colloidal silicic acid. After adding a 10% gelatin solution to this mixture, it was ground and passed through a 14 mesh sieve. This was dried, and 160 g of potato starch, 50 g of talc, and 5 g of magnesium stearate were added thereto, and the resulting mixture was made into tablets.
<제제예 2. 식품 제조><Formulation Example 2. Food Manufacturing>
제제예 2-1. 조리용 양념의 제조Formulation Example 2-1. Preparation of cooking seasonings
실시예 1의 견사단백질을 갖는 익힌 누에가공물 분말을 조리용 양념에 1 중량%로 첨가하여 건강 증진용 조리용 양념을 제조하였다.A cooking seasoning for health promotion was prepared by adding the cooked silkworm processed powder having the silk protein of Example 1 to the cooking seasoning in an amount of 1% by weight.
제제예 2-2. 밀가루 식품의 제조Formulation Example 2-2. Flour food manufacturing
실시예 1의 견사단백질을 갖는 익힌 누에가공물 분말을 밀가루에 0.1 중량%로 첨가하고, 이 혼합물을 이용하여 빵, 케이크, 쿠키, 크래커 및 면류를 제조하여 건강 증진용 식품을 제조하였다.The cooked silkworm processed powder having the silk protein of Example 1 was added to wheat flour in an amount of 0.1 wt%, and the mixture was used to prepare bread, cake, cookies, crackers and noodles to prepare health-promoting food.
제제예 2-3. 스프 및 육즙(gravies)의 제조Formulation Example 2-3. Preparation of soups and gravies
실시예 1의 견사단백질을 갖는 익힌 누에가공물 분말을 스프 및 육즙에 0.1 중량%로 첨가하여 건강 증진용 수프 및 육즙을 제조하였다.Soup and broth for health promotion were prepared by adding the cooked silkworm processed powder having the silk protein of Example 1 to the soup and broth in an amount of 0.1% by weight.
제제예 2-4. 유제품(dairy products)의 제조Formulation Example 2-4. Manufacture of dairy products
실시예 1의 견사단백질을 갖는 익힌 누에가공물 분말을 우유에 0.1 중량%로 첨가하고, 상기 우유를 이용하여 버터 및 아이스크림과 같은 다양한 유제품을 제조하였다.The cooked silkworm processed powder having the silk protein of Example 1 was added to milk in an amount of 0.1% by weight, and various dairy products such as butter and ice cream were prepared using the milk.
제제예 2-5. 야채주스 제조Formulation Example 2-5. vegetable juice production
실시예 1의 견사단백질을 갖는 누에가공물 분말을 토마토주스 또는 당근주스에 0.5 중량%로 첨가하여 건강증진용 야채주스를 제조하였다.A vegetable juice for health promotion was prepared by adding the processed silkworm powder having the silk protein of Example 1 to tomato juice or carrot juice in an amount of 0.5% by weight.
제제예 2-6. 과일주스 제조Formulation Example 2-6. fruit juice production
실시예 1의 견사단백질을 갖는 누에가공물 분말을 사과주스 또는 포도주스 0.1 중량%로 첨가하여 건강 증진용 과일주스를 제조하였다.Fruit juice for health promotion was prepared by adding the processed silkworm powder having the silk protein of Example 1 at 0.1% by weight of apple juice or grape juice.
Claims (10)
상기 익힌 누에 가공물은, 5령4일의 4면잠 누에부터 숙잠기까지의 누에 중에서 선택되는 견사단백질을 갖는 생누에를 55 내지 125℃의 온도에서 30분 내지 24시간 동안 물에 넣어 익히거나 또는 증기의 열로 익혀 제조한 것을 특징으로 하는, 내장 지방형 비만의 예방 또는 치료용 약학적 조성물.
As a pharmaceutical composition for the prevention or treatment of visceral fat-type obesity, comprising as an active ingredient a cooked silkworm processing product having silk protein,
The cooked silkworm process is a raw silkworm having a silk protein selected from silkworms selected from silkworms from 5 instar and 4 days of sleep to deep sleep in water at a temperature of 55 to 125° C. for 30 minutes to 24 hours to cook or steam. A pharmaceutical composition for the prevention or treatment of visceral fat-type obesity, characterized in that it is prepared by cooking with the heat of.
상기 조성물은, 체중 및 내장 지방을 감소시키고, 내장 지방의 축적 및 체중의 증가를 억제시키는 것을 특징으로 하는,
내장 지방형 비만의 예방 또는 치료용 약학적 조성물.
The method of claim 1,
The composition, characterized in that it reduces body weight and visceral fat, and inhibits accumulation of visceral fat and increase in body weight,
A pharmaceutical composition for the prevention or treatment of visceral fat-type obesity.
상기 익힌 누에가공물은 열풍건조 또는 진공동결건조물인 것을 특징으로 하는,
내장 지방형 비만의 예방 또는 치료용 약학적 조성물.
The method of claim 1,
The cooked silkworm process is characterized in that the hot air drying or vacuum freeze-dried product,
A pharmaceutical composition for the prevention or treatment of visceral fat-type obesity.
상기 익힌 누에 가공물은, 5령4일의 4면잠 누에부터 숙잠기까지의 누에 중에서 선택되는 견사단백질을 갖는 생누에를 55 내지 125℃의 온도에서 30분 내지 24시간 동안 물에 넣어 익히거나 또는 증기의 열로 익혀 제조한 것을 특징으로 하는, 내장 지방형 비만의 예방 또는 개선용 식품 조성물.
As a food composition for the prevention or improvement of visceral fat-type obesity, comprising a cooked silkworm processed product having silk protein as an active ingredient,
The cooked silkworm process is a raw silkworm having a silk protein selected from silkworms selected from silkworms from 5 instar and 4 days of sleep to deep sleep in water at a temperature of 55 to 125° C. for 30 minutes to 24 hours to cook or steam. Food composition for the prevention or improvement of visceral fat-type obesity, characterized in that it is prepared by cooking with the heat of.
상기 식품 조성물은 건강기능식품, 식품 첨가제 또는 식이보조제인 것을 특징으로 하는,
내장 지방형 비만의 예방 또는 개선용 식품 조성물.
7. The method of claim 6,
The food composition is characterized in that it is a health functional food, food additive or dietary supplement,
A food composition for preventing or improving visceral fat-type obesity.
상기 익힌 누에 가공물은, 5령4일의 4면잠 누에부터 숙잠기까지의 누에 중에서 선택되는 견사단백질을 갖는 생누에를 55 내지 125℃의 온도에서 30분 내지 24시간 동안 물에 넣어 익히거나 또는 증기의 열로 익혀 제조한 것을 특징으로 하는, 체중 증가 억제 또는 내장 지방 감소용 건강기능 식품 조성물.
As a health functional food composition for weight gain suppression or visceral fat reduction comprising cooked silkworm processed material having silk protein as an active ingredient,
The cooked silkworm process is a raw silkworm having a silk protein selected from silkworms selected from silkworms from 5 instar and 4 days of sleep to deep sleep in water at a temperature of 55 to 125° C. for 30 minutes to 24 hours to cook or steam. A health functional food composition for weight gain inhibition or visceral fat reduction, characterized in that it is prepared by cooking with the heat of
상기 익힌 누에 가공물은, 5령4일의 4면잠 누에부터 숙잠기까지의 누에 중에서 선택되는 견사단백질을 갖는 생누에를 55 내지 125℃의 온도에서 30분 내지 24시간 동안 물에 넣어 익히거나 또는 증기의 열로 익혀 제조한 것이고;
상기 비만으로 인한 합병증은 내장 지방 증후군, 대사이상 증후군, 고트리글리세라이드 혈증, 저HDL 혈증, 폐고혈압, 당뇨병, 고혈압, 손상된 내당력, 만성 동맥폐색증, 지질증후군 및 과혈당증으로 구성된 군으로부터 선택되는 1 종 이상인 것을 특징으로 하는,
비만으로 인한 합병증의 예방 또는 치료용 약학적 조성물.
As a pharmaceutical composition for the prevention or treatment of complications due to obesity, comprising as an active ingredient a cooked silkworm processing product having silk protein,
The cooked silkworm process is a raw silkworm having a silk protein selected from silkworms selected from silkworms from 5 instar and 4 days of sleep to deep sleep in water at a temperature of 55 to 125° C. for 30 minutes to 24 hours to cook or steam. It is prepared by cooking with the heat of;
Complications due to obesity include visceral fatty syndrome, metabolic syndrome, hypertriglyceridemia, hypoHDLemia, pulmonary hypertension, diabetes, hypertension, impaired glucose tolerance, chronic arterial occlusion, lipid syndrome, and hyperglycemia. characterized by more than
A pharmaceutical composition for preventing or treating complications due to obesity.
상기 익힌 누에 가공물은, 5령4일의 4면잠 누에부터 숙잠기까지의 누에 중에서 선택되는 견사단백질을 갖는 생누에를 55 내지 125℃의 온도에서 30분 내지 24시간 동안 물에 넣어 익히거나 또는 증기의 열로 익혀 제조한 것이고;
상기 비만으로 인한 합병증은 내장 지방 증후군, 대사이상 증후군, 고트리글리세라이드 혈증, 저HDL 혈증, 폐고혈압, 당뇨병, 고혈압, 손상된 내당력, 만성 동맥폐색증, 지질증후군 및 과혈당증으로 구성된 군으로부터 선택되는 1 종 이상인 것을 특징으로 하는,
비만으로 인한 합병증의 예방 또는 개선용 식품 조성물.
As a food composition for the prevention or improvement of complications due to obesity, comprising as an active ingredient a processed silkworm with silk protein,
The cooked silkworm process is a raw silkworm having a silk protein selected from silkworms selected from silkworms from 5 instar and 4 days of sleep to deep sleep in water at a temperature of 55 to 125° C. for 30 minutes to 24 hours to cook or steam. It is prepared by cooking with the heat of;
Complications due to obesity include visceral fatty syndrome, metabolic syndrome, hypertriglyceridemia, hypoHDLemia, pulmonary hypertension, diabetes, hypertension, impaired glucose tolerance, chronic arterial occlusion, lipid syndrome, and hyperglycemia. characterized by more than
A food composition for preventing or improving complications due to obesity.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20190073030 | 2019-06-19 | ||
| KR1020190073030 | 2019-06-19 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20200145745A KR20200145745A (en) | 2020-12-30 |
| KR102436692B1 true KR102436692B1 (en) | 2022-08-26 |
Family
ID=74088333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020200074840A KR102436692B1 (en) | 2019-06-19 | 2020-06-19 | Composition comprising steamed mature silkworm products having silk protein for preventing or treating obesity |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102436692B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102590057B1 (en) | 2023-03-14 | 2023-10-17 | (주)씨앤비오 | Food composition using silkworm extract protein |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101173546B1 (en) | 2011-08-18 | 2012-08-13 | 충북대학교 산학협력단 | An anti-obesity composition containing fat-removed silkworm pupa hydrolysate and its manufacturing method |
| KR101546446B1 (en) | 2013-06-24 | 2015-08-24 | 대한민국 | Health functional food and cosmetic composition containing silkworm products having silk protein |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110105627A (en) * | 2010-03-19 | 2011-09-27 | 주식회사 엘지생활건강 | Anti-obesity composition containing silkworm hemolymph |
| KR101388455B1 (en) | 2012-09-20 | 2014-04-23 | 대한민국 | Processing method of silkworm having silk protein and silkworm processed goods by its |
-
2020
- 2020-06-19 KR KR1020200074840A patent/KR102436692B1/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101173546B1 (en) | 2011-08-18 | 2012-08-13 | 충북대학교 산학협력단 | An anti-obesity composition containing fat-removed silkworm pupa hydrolysate and its manufacturing method |
| KR101546446B1 (en) | 2013-06-24 | 2015-08-24 | 대한민국 | Health functional food and cosmetic composition containing silkworm products having silk protein |
Non-Patent Citations (1)
| Title |
|---|
| Sun Hee Lee 외. Silk and silkworm pupa peptides suppress adipogenesis in preadipocytes and fat accumulation in rats fed a high-fat diet. Eur J Nutr, 2012, Vol. 51, pp. 1011-1019* |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102590057B1 (en) | 2023-03-14 | 2023-10-17 | (주)씨앤비오 | Food composition using silkworm extract protein |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200145745A (en) | 2020-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102257023B1 (en) | Composition comprising Oenothera biennis extract for preventing, treating or improving muscular atrophy or sarcopenia | |
| KR101523812B1 (en) | Composition comprising extract of Humulus japonicus or Humulus scandens for preventing or treating of metabolic diseases | |
| KR102110040B1 (en) | Composition for preventing and treating of obesity or metabolic disease comprising Elaeagnus umbellata extracts | |
| KR20120002131A (en) | Composition for treating or preventing obesity containing curcuma longa extract | |
| KR20120003693A (en) | Anti-obesity composition comprising red grape extracts, green tea extracts, soybean extracts, and l-carnitine | |
| KR101785495B1 (en) | Composition comprising Chrisanthemum indicum extract or fraction for treating, improving or preventing obesity or obesity-related disease | |
| KR102436692B1 (en) | Composition comprising steamed mature silkworm products having silk protein for preventing or treating obesity | |
| KR101497109B1 (en) | Composition for preventing, improving, or treating a disease controlled by PPAR action | |
| KR20130047458A (en) | Composition for preventing, improving, or treating a disease controlled by ppar action | |
| KR20210130588A (en) | Composition for anti-obesity comprising extract of Sargassum horneri | |
| KR20110105627A (en) | Anti-obesity composition containing silkworm hemolymph | |
| KR101509796B1 (en) | Composition for preventing or treating obesity comprising blueberry fermentation extract | |
| KR101445966B1 (en) | A composition comprising Amomum cardamomum L. extracts having anti-obesity activity | |
| KR102354367B1 (en) | Manufacturing method of low molecular peptide from edible insects and composition for muscle improving comprising its prepared thereby | |
| KR101851639B1 (en) | Composition for anti-obesity comprising Chaenomelis Fructus extract or its fraction as effective component | |
| KR101594979B1 (en) | Compositions for treating or preventing obesity containing extract or fractions of Euphorbia supina Raf. | |
| JP6273440B2 (en) | GLP-1 production promoter, DPPIV inhibitor and glucose absorption inhibitor | |
| KR20110121849A (en) | Composition for prevention or treatment of obesity or hyperlipedemia comprising the extracts of gymnaster koraiensis or artemisia dubia | |
| KR102151011B1 (en) | Composition for preventing, improving or treating liver disease comprising fermented liquor of aged sprout ginseng extract as effective component | |
| KR20160059152A (en) | Anti-obesity composition comprising Cirsium japonicum leaf extract as effective component | |
| KR102496752B1 (en) | Fruits of Acanthopanax Sessiliflorus extract including alcoholic liver injury prevention functional ingredients and method for manufacturing it | |
| KR100888068B1 (en) | Compositions for suppressing obesity | |
| KR102183916B1 (en) | Composition containing complex extracts for preventing, improving or treating dyslipidemia | |
| KR102183915B1 (en) | Composition containing complex extracts for improving blood circulation | |
| KR102236685B1 (en) | Composition for preventing or treating lipid metabolism diseases comprising extract of salvia miltiorrhiza or paeonia lactiflora |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |